Paula Peyrani1, Forest W Arnold2, Jose Bordon3, Stephen Furmanek2, Carlos M Luna4, Rodrigo Cavallazzi5, Julio Ramirez2. 1. Vaccines Clinical Research and Development, Pfizer Inc, Collegeville, PA. Electronic address: paulapeyrani@gmail.com. 2. Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Louisville, Louisville, KY. 3. Section of Infectious Diseases, Providence Hospital, Washington, DC. 4. Department of Medicine, Pulmonary Diseases Division, Hospital de Clínicas, Universidad de Buenos Aires, Buenos Aires, Argentina. 5. Division of Pulmonary, Critical Care, and Sleep Disorders, Department of Medicine, School of Medicine, University of Louisville, Louisville, KY.
Abstract
BACKGROUND: After hospitalization for community-acquired pneumonia (CAP), patients' clinical course may progress to clinical improvement, clinical failure, or nonresolving pneumonia. The epidemiology and outcomes of patients with CAP according to clinical course has not been well studied. The objective of this study was to characterize the incidence and outcomes for each clinical course of hospitalized patients with CAP. METHODS: This was a secondary data analysis of the University of Louisville Pneumonia Study. Clinical course was classified as improvement, failure, and nonresolving. Objective criteria were used to define improvement and failure during the first week of hospitalization. If neither group of criteria were met, the course was classified as nonresolving. Incidence for each clinical course was calculated. Mortality was evaluated at different time points through the first year. P < .05 was considered statistically significant. RESULTS: A total of 7,449 patients were hospitalized with CAP during the study period. Improvement was documented in 5,732 patients (77%), failure was documented in 1,458 patients (20%), and nonresolving CAP was documented in 259 patients (3%). Mortality at 30 days was 6% for those who improved, 34% for those who failed, and 34% for those with nonresolving pneumonia. Mortality at 1 year was 23%, 52%, and 51%, respectively. CONCLUSIONS: This study shows that > 75% of hospitalized patients with CAP will reach clinical improvement. One of two patients with clinical failure or nonresolving CAP may die 1 year after hospitalization. Understanding the pathogenesis of long-term mortality is critical to developing interventions.
BACKGROUND: After hospitalization for community-acquired pneumonia (CAP), patients' clinical course may progress to clinical improvement, clinical failure, or nonresolving pneumonia. The epidemiology and outcomes of patients with CAP according to clinical course has not been well studied. The objective of this study was to characterize the incidence and outcomes for each clinical course of hospitalized patients with CAP. METHODS: This was a secondary data analysis of the University of Louisville Pneumonia Study. Clinical course was classified as improvement, failure, and nonresolving. Objective criteria were used to define improvement and failure during the first week of hospitalization. If neither group of criteria were met, the course was classified as nonresolving. Incidence for each clinical course was calculated. Mortality was evaluated at different time points through the first year. P < .05 was considered statistically significant. RESULTS: A total of 7,449 patients were hospitalized with CAP during the study period. Improvement was documented in 5,732 patients (77%), failure was documented in 1,458 patients (20%), and nonresolving CAP was documented in 259 patients (3%). Mortality at 30 days was 6% for those who improved, 34% for those who failed, and 34% for those with nonresolving pneumonia. Mortality at 1 year was 23%, 52%, and 51%, respectively. CONCLUSIONS: This study shows that > 75% of hospitalized patients with CAP will reach clinical improvement. One of two patients with clinical failure or nonresolving CAP may die 1 year after hospitalization. Understanding the pathogenesis of long-term mortality is critical to developing interventions.
Authors: Neha A Sathe; Leila R Zelnick; Carmen Mikacenic; Eric D Morrell; Pavan K Bhatraju; J Brennan McNeil; Susanna Kosamo; Catherine L Hough; W Conrad Liles; Lorraine B Ware; Mark M Wurfel Journal: Crit Care Date: 2021-09-15 Impact factor: 19.334
Authors: Abla Tannous; Susan L Levinson; James Bolognese; Steven M Opal; Mark J DiNubile Journal: Antimicrob Agents Chemother Date: 2020-09-21 Impact factor: 5.191
Authors: Adam Greenfield; Kassandra Marsh; Justin Siegfried; Ioannis Zacharioudakis; Nabeela Ahmed; Arnold Decano; Maria E Aguero-Rosenfeld; Kenneth Inglima; John Papadopoulos; Yanina Dubrovskaya Journal: Open Forum Infect Dis Date: 2021-10-22 Impact factor: 3.835
Authors: Christian Theilacker; Ralf Sprenger; Friedhelm Leverkus; Jochen Walker; Dennis Häckl; Christof von Eiff; Julia Schiffner-Rohe Journal: PLoS One Date: 2021-06-15 Impact factor: 3.240
Authors: Charles S Dela Cruz; Scott E Evans; Marcos I Restrepo; Nathan Dean; Antonio Torres; Isabel Amara-Elori; Shanjana Awasthi; Elisabet Caler; Bin Cao; James D Chalmers; Jean Chastre; Taylor S Cohen; Alan H Cohen; Kristina Crothers; Y Peter Di; Marie E Egan; Charles Feldman; Samir Gautam; E Scott Halstead; Susanne Herold; Barbara E Jones; Carlos Luna; Michael S Niederman; Raul Mendez; Rosario Menendez; Joseph P Mizgerd; Roomi Nusrat; Julio Ramirez; Yuichiro Shindo; Grant Waterer; Samantha M Yeligar; Richard G Wunderink Journal: Ann Am Thorac Soc Date: 2021-07